Jeremy Barton

3.0k total citations
38 papers, 1.5k citations indexed

About

Jeremy Barton is a scholar working on Oncology, Pathology and Forensic Medicine and Materials Chemistry. According to data from OpenAlex, Jeremy Barton has authored 38 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 7 papers in Materials Chemistry. Recurrent topics in Jeremy Barton's work include HER2/EGFR in Cancer Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Jeremy Barton is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Jeremy Barton collaborates with scholars based in United States, United Kingdom and Italy. Jeremy Barton's co-authors include Teri W. Odom, Eric C. Greyson, Christopher L. Stender, Joel Henzie, G. Blackledge, Alan E. Wakeling, Christine E. Swenson, Lauri Welles, Gerald Batist and Philip Chaikin and has published in prestigious journals such as Journal of the American Chemical Society, Advanced Materials and Journal of Clinical Oncology.

In The Last Decade

Jeremy Barton

37 papers receiving 1.4k citations

Peers

Countries citing papers authored by Jeremy Barton

Since Specialization

Citations

This map shows the geographic impact of Jeremy Barton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Barton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Barton more than expected).

Fields of papers citing papers by Jeremy Barton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Barton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Barton. The network helps show where Jeremy Barton may publish in the future.

Co-authorship network of co-authors of Jeremy Barton

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Barton. A scholar is included among the top collaborators of Jeremy Barton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Barton. Jeremy Barton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trial in Progress: ST-067 (decoy-resistant IL-18) with Teclistamab in Multiple Myeloma 2024 ·Blood ·Rahul Banerjee, (unknown), Jeremy Barton, (unknown), (unknown), Jordan Gauthier, Aaron M. Ring, Ajay K. Gopal, Geoffrey R. Hill, (unknown)	1
2	736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies 2023 ·SHILAP Revista de lepidopterología ·Justin C. Moser, Ryan J. Sullivan, Matthew H. Taylor, Igor Puzanov, Gerald S. Falchook, Mario Sznol, (unknown), (unknown), (unknown), (unknown), Hirdesh Uppal, Jeremy Barton, (unknown), Aaron M. Ring, Harriet M. Kluger	2
3	Origin of metastable oligomers and their effects on amyloid fibril self-assembly 2018 ·Chemical Science ·(unknown), Tatiana Miti, Carlos J. Pérez-Rivera, Jeremy Barton, (unknown), Lothar Gremer, (unknown), Garrett Matthews, Georg Meisl, Tuomas P. J. Knowles, Dieter Willbold, Philipp Neudecker, Henrike Heise, Ghanim Ullah, Wolfgang Hoyer, Martin Muschol	80
4	First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors 2017 ·Investigational New Drugs ·Geoffrey I. Shapiro, Ulka N. Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Y. Hua, Steven D. Reich, Ronald Shazer, Carrie Turich Taylor, Dawei Xuan, Hossein Borghaei	32
5	Applying the best of oncology drug development paradigms to the non-malignant space 2016 ·Drug Discovery Today ·Indranil Bhattacharya, Anne C. Heatherington, Jeremy Barton	3
6	Anterior tumors of the prostate: clinicopathological features and outcomes 2013 ·Prostate Cancer and Prostatic Diseases ·(unknown), Isabell A. Sesterhenn, Inger L. Rosner, (unknown), Jennifer Cullen, (unknown), Jeremy Barton, Albert Dobi, Shiv Srivastava, D. G. R. McLeod, (unknown)	36
7	Patent Landscape of Influenza A Virus Prophylactic Vaccines and Related Technologies 2012 ·University of New Hampshire Scholars Repository (University of New Hampshire at Manchester) ·(unknown), S. P. Kowalski, David L. Pflugh, Jeremy Barton, (unknown), (unknown)	1
8	Chemical Patterning of Ultrathin Polymer Films by Direct-Write Multiphoton Lithography 2011 ·Journal of the American Chemical Society ·Hojeong Jeon, (unknown), Jeremy Barton, David J. Hwang, Lara J. Gamble, David G. Castner, Costas P. Grigoropoulos, Kevin E. Healy	43
9	A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer 2011 ·Gynecologic Oncology ·Katherine M. Bell‐McGuinn, Carolyn M. Matthews, Steffan N. Ho, Minal Barve, Lucy Gilbert, Richard T. Penson, Ernst Lengyel, Rameshraja Palaparthy, Kye Gilder, Artemios B. Vassos, (unknown), (unknown), Jeremy Barton, Russell J. Schilder	144
10	Structural control of anodized tantalum oxide nanotubes 2009 ·Journal of Materials Chemistry ·Jeremy Barton, Christopher L. Stender, Phoebe Li, Teri W. Odom	34
11	Shape-Control of Protein Crystals in Patterned Microwells 2008 ·Journal of the American Chemical Society ·Liying Wang, Min Hyung Lee, Jeremy Barton, Laura D. Hughes, Teri W. Odom	26
12	A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma 2008 ·Journal of Clinical Oncology ·Jeremy Barton	10
13	Tetrahedral Zinc Blende Tin Sulfide Nano‐ and Microcrystals 2006 ·Small ·Eric C. Greyson, Jeremy Barton, Teri W. Odom	175
14	Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL). 2005 ·Blood ·Madeleine Duvic, Joy H. Kunishige, Youn H. Kim, (unknown), Lauren Pinter‐Brown, Mark U. Rarick, John A. Zic, Sophie M. Worobec, Francine M. Foss, Karen A. Flessland, Jeremy Barton	2
15	Mass-Limited Growth in Zeptoliter Beakers: A General Approach for the Synthesis of Nanocrystals 2004 ·Nano Letters ·Jeremy Barton, Teri W. Odom	71
16	Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy 2002 ·Expert Opinion on Pharmacotherapy ·Gerald Batist, Jeremy Barton, Philip Chaikin, Christine E. Swenson, Lauri Welles	133
17	Growth factors and their receptors: new targets for prostate cancer therapy 2001 ·Urology ·Jeremy Barton, G. Blackledge, Alan E. Wakeling	92
18	Anti-EGF receptor therapy 2000 ·Prostate Cancer and Prostatic Diseases ·G. Blackledge, (unknown), Andrea Kay, Jeremy Barton	15
19	Smoking among secondary school children in 1996 : Scotland : an enquirycarried out by Social Survey Division of ONS on behalf of the Scottish Office Department of Health 1997 ·Jeremy Barton, (unknown)	1
20	Characterization of the surface acid-base properties of metal oxides by titration/displacement reactions 1986 ·The Journal of Physical Chemistry ·Roger Spitz, Jeremy Barton, Mark A. Barteau, R. H. STALEY, A. W. Sleight	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact